BGPT: Best Evidence:

Explore by Goal

Quick Explanation Copied

Best Evidence audit (skeptical, method-first)

The supplied “Best Evidence” set contains (i) a network meta-analysis on vestibular migraine preventives, and (ii) methodological evidence (GRADE inconsistency) that directly tells you when to downgrade certainty—especially when results are mostly indirect and heterogeneity/inconsistency can’t be explained.

Long Explanation

Evidence battle-test: what the “Best Evidence” set supports vs. what it can’t

April 03, 2026 — skeptical, evidence-quality focused, with inline scientific citations.

1) Identify the claim type(s) in the supplied evidence

Comparative efficacy/safety ranking for vestibular migraine preventives is supported by a systematic review + network meta-analysis, which is inherently sensitive to network structure, heterogeneity, and indirectness.
Methodological guidance for handling inconsistent/heterogeneous results and deciding when to downgrade certainty is directly provided by GRADE “inconsistency” guidance.
A separate thread exists in the dataset: an ecological meta-analysis arguing that high-level narratives about “alternative grazing” boosting soil organic carbon (SOC) are dominated by low-quality evidence, illustrating how “ranking narratives” can be driven by inclusion of weaker studies.

2) Visual evidence check A — vestibular migraine preventive hierarchy (indirectness risk)

The vestibular migraine NMA reports a ranking where propranolol has the largest mean reduction in monthly vertigo attacks based on indirect evidence (reported as −7.04 attacks/month), while valproic acid and venlafaxine are next (−5.95 and −5.94 respectively).

Skeptical constraint: Because head-to-head trials are limited and the network is described as star-shaped (limiting formal inconsistency checks), the order of therapies can be less certain than the direction “better than control.”

Plot 1 — Reported mean monthly vertigo reduction vs control (attacks/month)

3) Apply GRADE inconsistency logic to this ranking

GRADE’s inconsistency guidance tells you to ask: is inconsistency large and unexplained after exploring pre-specified reasons, and do subgroup explanations have credibility?

Indirectness + limited network loops weaken the ability to detect and resolve inconsistency (even when “all improve vs control”).
Endpoint and reporting heterogeneity (diagnostic criteria variability; adverse event reporting heterogeneity; short follow-up) plausibly increases unexplained variation, which—under GRADE thinking—should push certainty down unless credibility of explanations is high.

4) Visual evidence check B — SOC claims: why “overall means” can mislead

The SOC grazing meta-analysis reports an overall mean ln(RR) of 0.05 with 95% CI from −0.01 to −0.10, and it reports that when focusing on higher-quality primary studies, SOC response is indistinguishable from zero; the small positives are attributed to lower-quality/less representative studies.

Plot 2 — Reported SOC effect size (ln(RR)) with confidence interval

5) What’s the most defensible “take-home” from this evidence bundle?

Defensible: For vestibular migraine preventives, the NMA supports that evaluated options tend to reduce monthly vertigo attacks vs control, but the relative hierarchy is more uncertain because the ranking often comes from indirect comparisons with limited head-to-head coverage and constrained inconsistency testing.
Defensible: The GRADE inconsistency framework provides a rigorous rule-set for when uncertainty should be downgraded for inconsistent/heterogeneous results, reinforcing why indirect/reliance-heavy rankings should be treated cautiously.
Defensible (methodological analogy): In the SOC grazing meta-analysis, an apparent small overall positive signal does not remain when restricting to higher-quality primary evidence, illustrating how including weaker studies can shift effect estimates.

Most likely blind spots / what could change the conclusions

More head-to-head RCTs for vestibular migraine preventives could reorder (or collapse) the apparent hierarchy produced by indirect evidence.
Longer follow-up and more consistent adverse-event reporting could change safety/tolerability certainty.
Quality-restricted analyses could similarly attenuate or nullify ranked effect differences if lower-quality studies contribute disproportionately to the network estimate. This is the same failure mode demonstrated in the SOC grazing review.

Next targeted BGPT actions